🔗 Share this article The Global Health Body Issues Concern Over Critical Lack of Weight-Loss Medications Less than 10% of patients eligible to benefit from weight-loss injections including Wegovy are able to get them, caution the WHO as it releases its first recommendations on the therapies. With over a billion individuals worldwide currently obese, it is calling for more widespread and fairer availability to GLP-1 medication. Per forecasts, over two billion could be living with obesity by 2030 unless action is taken. "Our latest guidelines affirms that obesity is a chronic disease that can be treated with holistic and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are major hurdles to broad access to the injections that can help people shift considerable body mass, says the agency. Skinny Jab Scarcity Even in the current best projected scenario, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – less than 10% of eligible patients, as stated by the WHO. The recommendation calls on governments and firms to expand availability, by strategies including patent sharing. A patent on semaglutide – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026. How Obesity Jabs Work The injections imitate a biological compound to slow digestion, curb appetite and boost the sense of being full so users reduce food intake. Individuals typically begin shedding pounds within a few weeks of starting on the regular doses. Studies indicates patients may see weight return after a year of discontinuing the drug, as their normal hunger return. To be overweight or obese increases your chance for developing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies. Obesity concerns individuals in all nations and was responsible for millions of fatalities worldwide in 2024, per the health agency.
Less than 10% of patients eligible to benefit from weight-loss injections including Wegovy are able to get them, caution the WHO as it releases its first recommendations on the therapies. With over a billion individuals worldwide currently obese, it is calling for more widespread and fairer availability to GLP-1 medication. Per forecasts, over two billion could be living with obesity by 2030 unless action is taken. "Our latest guidelines affirms that obesity is a chronic disease that can be treated with holistic and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are major hurdles to broad access to the injections that can help people shift considerable body mass, says the agency. Skinny Jab Scarcity Even in the current best projected scenario, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – less than 10% of eligible patients, as stated by the WHO. The recommendation calls on governments and firms to expand availability, by strategies including patent sharing. A patent on semaglutide – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026. How Obesity Jabs Work The injections imitate a biological compound to slow digestion, curb appetite and boost the sense of being full so users reduce food intake. Individuals typically begin shedding pounds within a few weeks of starting on the regular doses. Studies indicates patients may see weight return after a year of discontinuing the drug, as their normal hunger return. To be overweight or obese increases your chance for developing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies. Obesity concerns individuals in all nations and was responsible for millions of fatalities worldwide in 2024, per the health agency.